KRKA-FARMA d.o.o. (manufacturer responsible for manufacturing 'in bulk', primary and secondary packaging, batch control, batch release)

The drug is indicated for the treatment of adults and children with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases, hypereosinophilic syndrome, and chronic eosinophilic leukemia. It is also used for the treatment of gastrointestinal stromal tumors (GIST) and dermatofibrosarcoma protuberans (DFSP).

Dosage form: tablets, film-coated

ATC: L01EA01

The drug is used for the treatment of adults and children with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic syndromes, hypereosinophilic syndrome, as well as for the treatment of certain types of tumors (GIST and desmoid tumors).

Dosage form: tablets, film-coated

ATC: L01EA01